C
22.54
0.21 (0.94%)
| Previous Close | 22.33 |
| Open | 22.27 |
| Volume | 993,280 |
| Avg. Volume (3M) | 1,305,843 |
| Market Cap | 3,030,454,528 |
| Price / Sales | 260.89 |
| Price / Book | 14.39 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -205.18% |
| Diluted EPS (TTM) | -1.88 |
| Total Debt/Equity (MRQ) | 30.55% |
| Current Ratio (MRQ) | 14.37 |
| Operating Cash Flow (TTM) | -162.02 M |
| Levered Free Cash Flow (TTM) | -106.95 M |
| Return on Assets (TTM) | -28.58% |
| Return on Equity (TTM) | -74.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Centessa Pharmaceuticals plc | Bullish | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.80 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 94.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Index Venture Life Associates Vi Ltd | 30 Jun 2025 | 9,961,789 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 43.00 (Guggenheim, 90.77%) | Buy |
| Median | 35.00 (55.28%) | |
| Low | 35.00 (Stephens & Co., 55.28%) | Buy |
| 35.00 (Wells Fargo, 55.28%) | Buy | |
| Average | 37.67 (67.13%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 26.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 18 Nov 2025 | 43.00 (90.77%) | Buy | 28.36 |
| 06 Oct 2025 | 28.00 (24.22%) | Buy | 23.00 | |
| Wells Fargo | 13 Nov 2025 | 35.00 (55.28%) | Buy | 25.97 |
| 07 Nov 2025 | 30.00 (33.10%) | Buy | 22.12 | |
| Stephens & Co. | 28 Oct 2025 | 35.00 (55.28%) | Buy | 25.00 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BUSH TIA L | - | 27.32 | -40,000 | -1,092,800 |
| HUSSAIN IQBAL J | - | 27.32 | -6,000 | -163,920 |
| Aggregate Net Quantity | -46,000 | |||
| Aggregate Net Value ($) | -1,256,720 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 27.32 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BUSH TIA L | Officer | 17 Nov 2025 | Automatic sell (-) | 40,000 | 27.32 | 1,092,800 |
| BUSH TIA L | Officer | 17 Nov 2025 | Option execute | 40,000 | - | - |
| HUSSAIN IQBAL J | Officer | 17 Nov 2025 | Automatic sell (-) | 6,000 | 27.32 | 163,920 |
| HUSSAIN IQBAL J | Officer | 17 Nov 2025 | Option execute | 6,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |